RenovoRx shares surge 12.02% premarket after CMO Ramtin Agah buys 22,000 shares in $17,600 purchase.

RenovoRx surged 12.02% in premarket trading following a significant insider purchase by Chief Medical Officer and 10% owner Ramtin Agah, who acquired 22,000 shares at $0.8 per share, totaling $17,600. The transaction, disclosed via an SEC Form 4 filing, signals strong confidence in the company’s prospects from a key executive with substantial ownership stakes. Insider buying is often interpreted as a bullish signal, as it aligns management’s interests with shareholders and suggests the stock may be undervalued. Agah’s purchase, combined with his dual role as a senior officer and major stakeholder, likely reinforced investor optimism ahead of the market open, driving the sharp premarket gain.